Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Crossref DOI link: https://doi.org/10.1007/s40273-016-0386-z
Published Online: 2016-02-18
Published Print: 2016-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Squires, Hazel
Stevenson, Matt
Simpson, Emma
Harvey, Rebecca
Stevens, John
Funding for this research was provided by:
National Institute for Health Research Health Technology Assessment Programme (project number 12/65/01 STA)
Text and Data Mining valid from 2016-02-18